A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cancer
- Focus Proof of concept; Therapeutic Use
- 08 Mar 2018 Planned End Date changed from 1 Jan 2020 to 1 Mar 2021.
- 08 Mar 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2020.
- 29 Dec 2016 Status changed from not yet recruiting to recruiting.